Patent application number | Description | Published |
20100029498 | SELECTION OF NUCLEIC ACIDS BY SOLUTION HYBRIDIZATION TO OLIGONUCLEOTIDE BAITS - Methods of selection of nucleic acids using solution hybridization, methods of sequencing nucleic acids including such selection methods, and products for use in the methods are disclosed. | 02-04-2010 |
20100240101 | Parallel Proximity Ligation Event Analysis - The present invention describes compositions and methods showing that the spatial proximity of intracellular components may be related to their ability to cooperate in intracellular biochemical reactions. In some embodiments, the present invention contemplates a variety of nucleic acid barcoded binding partners capable of determining the spatial proximity of intracellular components as determined by ligation of their respective nucleotide barcodes. As such, an intracellular component contact map may be constructed to fingerprint specific physiological and/or pharmacological intracellular conditions. | 09-23-2010 |
20130096009 | METHODS OF IDENTIFYING INTERACTIONS BETWEEN GENOMIC LOCI - The disclosed Hi-C protocol can identify genomic loci that are spatially co-located in vivo. These spatial co-locations may include, but are not limited to, intrachromosomal interactions and/or interchromosomal interactions. Hi-C techniques may be applied to many different scales of interest. For example, on a large scale, Hi-C techniques can be used to identify long-range interactions between distant genomic loci. | 04-18-2013 |
20130230857 | HYBRID SELECTION USING GENOME-WIDE BAITS FOR SELECTIVE GENOME ENRICHMENT IN MIXED SAMPLES - The present invention provides methods for sequencing and genotyping of DNA useful for analysis of samples in which the target DNA represents a small portion (e.g., 10-1000-fold less) that a contaminating DNA source. Accordingly, the methods described herein are useful for sequencing or genotyping pathogen DNA, such as malaria DNA, in clinical samples taken from infected subjects. | 09-05-2013 |
20140200163 | MULTIPLEXED GENETIC REPORTER ASSAYS AND COMPOSITIONS - The invention provides methods for determining the activity of a plurality of nucleic acid regulatory elements. These methods may facilitate, e.g., the systematic reverse engineering, and optimization of mammalian cis-regulatory elements at high resolution and at a large scale. The method may include integration of multiplexed DNA synthesis and sequencing technologies to generate and quantify the transcriptional regulatory activity of e.g., thousands of arbitrary DNA sequences in parallel in cell-based as says (e.g., mammalian cell based assays). | 07-17-2014 |
Patent application number | Description | Published |
20100204051 | Hereditary Hemochromatosis Gene - The invention relates generally to the gene, and mutations thereto, that are responsible for the disease hereditary hemochromatosis (HH). More particularly, the invention relates to the identification, isolation, and cloning of the DNA sequence corresponding to the normal and mutant HH genes, as well as the characterization of their transcripts and gene products. The invention also related to methods and the like for screening for HH homozygotes and further relates to HH diagnosis, prenatal screening and diagnosis, and therapies of HH disease, including gene therapeutics, protein and antibody based therapeutics, and small molecule therapeutics. | 08-12-2010 |
20110269122 | HEREDITARY HEMOCHROMATOSIS GENE - The invention relates generally to the gene, and mutations thereto, that are responsible for the disease hereditary hemochromatosis (HH). More particularly, the invention relates to the identification, isolation, and cloning of the DNA sequence corresponding to the normal and mutant HH genes, as well as the characterization of their transcripts and gene products. The invention also related to methods and the like for screening for HH homozygotes and further relates to HH diagnosis, prenatal screening and diagnosis, and therapies of HH disease, including gene therapeutics, protein and antibody based therapeutics, and small molecule therapeutics. | 11-03-2011 |